Engy › Who's who in longevity › Andrea Maier

Andrea Maier

🇳🇱 🇸🇬
Professor of gerontology (VU Amsterdam / NUS)
DoctorScienceNL
LongevitySupplements
Last updated: 7 October 2026

At a glance

  • Internist-geriatrician and professor; active at VU Amsterdam and the National University of Singapore.
  • Focuses on geroscience: measuring and influencing ageing processes in clinical trials.
  • Named a TIME Longevity Leader (2026); advocates for better evidence in longevity.
  • Works on NMN dosing and personalised interventions (ACCURATE), among other things.

Known positions

Longevity

Longevity claims must be tested clinically, not just on social media

Maier emphasises benchmarks, trials and transparency — as opposed to hype without endpoints.

What does the science say? Strong evidenceSource: TIME Longevity Leaders ↗
Supplements

NMN can raise NAD+; dose-response and functional benefit need research

A multicentre RCT found NMN up to 900 mg/day safe in the short term, with effects on NAD+ and walking distance; long-term outcomes are lacking.

What does the science say? MixedSource: Yi et al., GeroScience ↗
Longevity

Personalised (AI-guided) dosing may be better than fixed doses

ACCURATE is investigating whether individual NMN adjustment optimises NAD+ better than standard dosing — results to follow.

What does the science say? Little evidenceSource: NUS Longevity Academy ACCURATE ↗

The ‘What does the science say?’ rating is an estimate by the Engy editors based on the cited source and the wider research. Not medical advice.

Criticism and nuance

With Maier too, the same applies: raising NAD+ is not proven life extension. Commercial longevity clinics and consumer products are moving faster than the trials.

Her public role balances scientific caution with visibility in a hype-driven market — something readers should keep a close eye on.

Recent

Where to follow them

More voices in longevity

See everyone →